MoonLake Immunotherapeutics
MLTX | NASDAQ
$12.55
+$0.16 (+1.29%)
At close: Sep 21, 2026, 4:00 PM ET
$12.54
-$0.01 (-0.08%)
Pre-market:
Sep 22, 2026, 6:40 AM ET
Company Profile
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Key Executives
| Name | Position |
|---|---|
| Jorge Santos da Silva | Co-Founder, Interim Chair of the Board & CEO |
| Matthias Bodenstedt | Chief Financial Officer |
| Carla Bretes | Director of Investor Relations & External Communications |
| Joana Cortez | Associate Vice-President of Legal & Compliance |
| Kristian Reich | Co-Founder & Chief Scientific Officer |
| Luciana Marques | Associate Vice-President of HR, People and Culture |
| Nicolas Mosimann | General Counsel |
| Nuala Brennan | Chief Clinical Development Officer |
| Oliver Daltrop | Chief Technical Officer |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 10, 2026 | S-8 | Filing |
| Aug 10, 2026 | S-3ASR | Automatic shelf registration statement of securiti... |
| Aug 10, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | 8-K | Current Report |
| Jul 29, 2026 | 4 | Filing |
| Jul 23, 2026 | 4 | Filing |
| Jul 21, 2026 | 4 | Filing |
MoonLake Immunotherapeutics
| Country | Switzerland |
| IPO Date | Oct 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Jorge Santos da Silva |
Stock Details
| Ticker Symbol | MLTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001821586 |
| CUSIP Number | 61559X104 |
| ISIN Number | KY61559X1045 |
| SIC Code | 2834 |
Recent News
- 14 days ago / seekingalpha.comMoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy
- 1 month ago / defenseworld.netMoonLake Immunotherapeutics Target of Unusually High Options Trading (NASDAQ:MLTX)
- 1 month ago / reuters.comMoonLake's psoriatic arthritis drug meets key goals in late-stage trial
- 1 month ago / globenewswire.comMoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
- 2 months ago / defenseworld.netArrowstreet Capital Limited Partnership Acquires New Shares in MoonLake Immunotherapeutics $MLTX
- 2 months ago / zacks.comWall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
- 3 months ago / fool.comMoonLake Immunotherapeutics' CFO Sells 39K Shares
- 3 months ago / seekingalpha.comMoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion
- 3 months ago / fool.comWhy MoonLake Immunotherapeutics Stock Wilted on Wednesday
- 3 months ago / globenewswire.comMoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
Add to Watchlist
Select watchlists to add or remove MLTX